2013-11-14T09:38:09-06:00 2012-12-31 841158905 CAUSEY DEMGEN & MOORE PC 1125 17TH ST STE 1450 DENVER CO 80202 990 2012-01-01 200499338 INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER INTE 7203252955 13100 E COLFAX AVE NO 10 AURORA CO 80011 FRED HIRSCH MD PHD 7203252955 2013-11-06 1 MICHAEL GRAEF P00038238 3032962229 2013-11-06 2012 2016-02-24 21:20:13Z FRED HIRSCH MD PHD 13100 E COLFAX AVE SUITE 10 AURORA CO 80011 3951233 0 X WWW.IASLC.ORG X 2003 CO TO PROMOTE THE STUDY OF THE ETIOLOGY, EPIDEMIOLOGY, PREVENTION, DIAGNOSIS, TREATMENT AND ALL OTHER ASPECTS OF LUNG CANCER AND OTHER THORACIC MALIGNANCIES.TO PROVIDE EDUCATION AND INFORMATION ABOUT LUNG CANCER AND OTHER THORACIC MALIGNANCIES TO IASLC MEMBERS, TO THE MEDICAL COMMUNITY AT LARGE, AND TO THE PUBLIC.TO USE ALL AVAILABLE MEANS TO ELIMINATE LUNG CANCER AND OTHER THORACIC MALIGNANCIES AS A HEALTH THREAT FOR THE INDIVIDUAL PATIENT AND THROUGHOUT THE WORLD. 19 19 9 0 -137476 0 505865 578966 12474708 3249356 177487 -46096 -553639 17363 12604421 3799589 404511 332273 0 0 648133 949659 0 0 0 11429000 3502025 12481644 4783957 122777 -984368 9138070 9162265 1591209 2151661 7546861 7010604 X TO PROMOTE THE STUDY OF THE ETIOLOGY, EPIDEMIOLOGY, PREVENTION, DIAGNOSIS, TREATMENT AND ALL OTHER ASPECTS OF LUNG CANCER AND OTHER THORACIC MALIGNANCIES.TO PROVIDE EDUCATION AND INFORMATION ABOUT LUNG CANCER AND OTHER THORACIC MALIGNANCIES TO IASLC MEMBERS, TO THE MEDICAL COMMUNITY AT LARGE, AND TO THE PUBLIC.TO USE ALL AVAILABLE MEANS TO ELIMINATE LUNG CANCER AND OTHER THORACIC MALIGNANCIES AS A HEALTH THREAT FOR THE INDIVIDUAL PATIENT AND THROUGHOUT THE WORLD. 0 0 332273 332273 213000 FELLOWSHIPS - PROVIDED TO TRAIN NEXT GENERATION OF LUNG CANCER LEADERS. FUNDING FOR IASLC FELLOWSHIP AND YOUNG INVESTIGATOR AWARDS PROVIDES FOR TRAINING OF FELLOWS AND YOUNG INVESTIGATORS WHO WISH TO PURSUE A CAREER IN DIAGNOSIS, TREATMENT, LABORATORY RESEARCH OR OTHER ASPECTS OF LUNG TUMORS.IASLC FELLOWSHIPS AND YOUNG INVESTIGATOR AWARDS ARE GRANTED FOR TWO YEARS. THE STIPEND FOR AN IASLC GRANT IS $40,000 PER YEAR. FUNDING FOR THE SECOND YEAR IS CONTINGENT UPON A SATISFACTORY PROGRESS REPORT AT THE ONE YEAR MARK. 758152 573311 PUBLICATIONS-PROVIDE EDUCATION TO THE WORLD WIDE LUNG CANCER COMMUNITY REGARDING THE LATEST ADVANCES IN LUNG CANCER TREATMENT. 2489135 1290986 MEETING AND WEB SEMINARS TO DISSEMINATE INFORMATION REGARDING THE LATEST ADVANCES IN LUNG CANCER TREATMENT. 3195 VARIOUS OTHER ACTIVITIES 3195 3579560 1 1 0 0 0 0 0 0 0 0 1 1 0 0 1 1 1 0 0 0 1 1 1 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 62 0 1 9 1 0 0 0 0 0 0 0 0 0 0 0 X 19 19 1 0 0 0 0 0 0 1 1 0 0 0 1 1 1 0 0 1 1 0 CO X JOHN WETHERINGTON 7203252955 13100 E COLFAX AVE SUITE 10 AURORA CO 80111 PETER GOLDSTRAW MB CHB FRCS 10.00 X X 0 0 0 TONY MOK MD 10.00 X X 0 0 0 FRED HIRSCH MD PHD 10.00 X X 0 0 0 MICHAEL BOYER MBBS PHD 3.00 X 0 0 0 KWUN FONG MBBS FRACP PHD 3.00 X 0 0 0 ALEX ADJEI MD PHD FACP 3.00 X 0 0 0 HISAO ASAMURA MD 3.00 X 0 0 0 DAVID CARBONE MD PHD 3.00 X 0 0 0 HAK CHOI MD 3.00 X 0 0 0 CAROLYN DRESLER MD MPA 3.00 X 0 0 0 DOMINIQUE GRUNENWALD MD 3.00 X 0 0 0 KAREN KELLY MD 3.00 X 0 0 0 CHRISTIAN MANEGOLD MD 3.00 X 0 0 0 TETSUYA MITSUDOMI MD PHD 3.00 X 0 0 0 KAZUHIKO NAKAGAWA MD PHD 3.00 X 0 0 0 SILVIA NOVELLO MD PHD 3.00 X 0 0 0 KEUNCHIL PARK MD PHD 3.00 X 0 0 0 ROLF STAHEL MD 3.00 X 0 0 0 SUMITRA THONGPRASERT MD 3.00 X 0 0 0 JOHAN VANSTEENKISTE MD PHD 3.00 X 0 0 0 DAVID GANDARA MD 10.00 X X 0 0 0 PAUL A BUNN JR MD 25.00 X 261000 0 32044 JOHN WETHERINGTON DBA 40.00 X 180000 0 16785 PIA HIRSCH 40.00 X 105633 0 7821 546633 0 56650 3 0 1 0 CLINICAL INSIGHTS INC 3431 2ND STREET OCEANSIDE NY 11572 WEB SEMINAR EXPENSES 468048 WOLTERS KLUWER HEALTH INC 16705 COLLECTION CENTER DRIVE CHICAGO IL 60693 PUBLISHER 333930 FAIRMONT HOTEL 101 WILSHIRE BOULEVARD SANTA MONICA CA 90401 MEETING EXPENSES 303179 INTERNATIONAL CONFERENCE SERVICES LTD 2101-1177 WEST HASTINGS STREET VANCOUVER ALBERTA CA WORLD CONFERENCE ORGANIZER 217571 CANCER RESEARCH & BIOSTATISTICS 1730 MINOR AVE SUITE 1900 SEATTLE WA 98101 VARIOUS 158303 5 503966 75000 578966 MEETING INCOME 541900 1793669 1213669 580000 WEB SEMINARS 541900 624376 77317 547059 LUNG CANCER JOURNAL 541900 514074 514074 FELLOWSHIP 541900 213000 213000 OTHER PUBLICATIONS 541900 104237 59237 45000 3249356 105548 105548 14168 0 14168 14168 14168 151644 -151644 -151644 -151644 MISCELLAENOUS INCOME 541900 3195 3195 3195 3799589 2080492 -137476 1277607 242273 242273 90000 90000 546633 409975 136658 261129 195846 65283 141897 106423 35474 6605 6605 93698 93698 41908 41908 10587 10587 73502 73502 58599 43949 14650 27670 20752 6918 108253 81190 27063 5997 5997 1544264 1076714 467550 37480 28110 9370 11287 11287 PUBLICATIONS 542238 542238 WEB SEMINARS 433773 433773 COMMITTEES 299317 299317 BANK FEES 59683 59683 147164 9000 138164 4783957 3579560 1204397 0 2356094 2102730 281469 2284071 928361 344522 743852 343430 37060 96783 306370 4056600 4799483 9138070 9162265 148787 385006 993831 1605422 448591 161233 1591209 2151661 X 7546861 7010604 7546861 7010604 9138070 9162265 -984368 448111 0 X X 0 1 X 1 0 X 2610443 13501446 3278409 6740411 505966 26636675 6240172 3324357 9564529 2610443 13501446 3278409 12980583 3830323 36201204 0 0 0 36201204 1359 89064 123174 114351 105548 433496 1359 89064 123174 114351 105548 433496 2611802 13590510 3401583 13094934 3935871 36634700 0.98820 0.01180 0.01230 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 95338 8092 87246 179842 28968 150874 68250 68250 306370 ALTERNATIVE INVESTMENTS 499291 F OTHER SECURITIES 4300192 F 4799483 DUE TO LOCAL CHAPTER FOR WCLC 2009 101970 DUE TO LOCAL CHAPTER CLCA 59263 161233 X 4240832 448111 -6868 441243 3799589 0 3799589 4777089 0 4777089 6868 6868 4783957 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X, LINE 2: THE ASSOCIATION HAS ADOPTED GUIDANCE ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. AFTER EVALUATING THE TAX POSITIONS TAKEN, NONE ARE CONSIDERED TO BE UNCERTAIN; THEREFORE, NO AMOUNTS HAVE BEEN RECOGNIZED AS OF DECEMBER 31, 2012 AND 2011. THE ASSOCICATION IS NO LONGER SUBJECT TO U.S. FEDERAL INCOME TAX EXAMINATIONS FOR YEARS PRIOR TO 2009. PART XI, LINE 2D - OTHER ADJUSTMENTS: FOREIGN CURRENCY LOSS -6,868. PART XII, LINE 4B - OTHER ADJUSTMENTS: FOREIGN CURRENCY LOSS 6,868. 1 SOUTH AMERICA 0 1 PROGRAM SERVICES SCIENTIFIC CONFERENCE 387181 EAST ASIA AND THE PACIFIC 0 1 PROGRAM SERVICES SCIENTIFIC CONFERENCE 60073 EUROPE (INCLUDING ICELAND & GREENLAND) 0 1 PROGRAM SERVICES SCIENTIFIC CONFERENCE 16621 0 3 0 0 0 3 463875 0 463875 EUROPE (INCLUDING ICELAND & GREENLAND) SUPPORT DEVELOPMENT OF RESEARCH & YOUNG MEDICAL PROFS. IN THORACIC ONCOLOGY. 20000 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) SUPPORT DEVELOPMENT OF RESEARCH & YOUNG MEDICAL PROFS. IN THORACIC ONCOLOGY. 10000 WIRE EAST ASIA AND THE PACIFIC SUPPORT DEVELOPMENT OF RESEARCH & YOUNG MEDICAL PROFS. IN THORACIC ONCOLOGY. 20000 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) SUPPORT DISSEMINATION OF LATEST RESEARCH & TREATMENTS FOR THORACIC ONCOLOGY. 10000 WIRE EAST ASIA AND THE PACIFIC SUPPORT DISSEMINATION OF LATEST RESEARCH & TREATMENTS FOR THORACIC ONCOLOGY. 10000 WIRE TO SUPPORT DEVELOPMENT OF RESEARCH AND YOUNG MEDICAL PROFESSIONALS IN THE AREA OF THORACIC ONCOLOGY. EAST ASIA AND THE PACIFIC 1 20000 WIRE 0 0 0 0 0 0 PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.: SCHEDULE F, PART I, LINE 2: 1. GRANTS WILL BE INITIALLY REVIEWED BY THE COMMITTEE CHAIR FOR COMPLETENESS. INCOMPLETE SUBMISSIONS OR GRANTS SUBMITTED AFTER THE DEADLINE WILL BE RETURNED TO THE PI IN 48 HOURS. 2. EACH MEMBER OF THE SCIENTIFIC REVIEW COMMITTEE WILL RIGOROUSLY REVIEW THE APPLICATIONS. APPLICATIONS WILL BE SCORED ON FOUR CRITERIA: A. POTENTIAL OF THE CANDIDATE: IS THE CANDIDATE COMMITTED TO A CAREER IN LUNG CANCER RESEARCH? DOES THE CANDIDATE HAVE BASIC TRAINING RELATED TO THE PROJECT PROPOSED? PUBLISHED/SUBMITTED PAPERS OR ABSTRACTS CURRENT OR PENDING GRANT SUBMISSIONS STRONG LETTERS OF SUPPORT B. SCIENTIFIC MERIT OF THE PROJECT: IS THE PROPOSAL ORIGINAL? IS THE PROPOSAL CLEAR & CONCISE? ARE THE SPECIFIC AIMS REASONABLE? IS THE METHODOLOGY REASONABLE TO ACCOMPLISH THE OBJECTIVES? CAN THE PROJECT BY COMPLETED IN THE 2 YEAR TIME FRAME? C. SIGNIFICANCE OF PROJECT: IS THE PROJECT WITHIN THE IASLC SCOPE? WHAT WILL THIS INFORMATION CONTRIBUTE TO KNOWLEDGE IN THIS FIELD? DO THESE RESULTS SIGNIFICANTLY IMPROVE THE APPLICATION OF KNOWLEDGE OF LUNG CANCER? WILL THESE DATA STIMULATE FURTHER SCIENTIFIC RESEARCH INTO LUNG CANCER? D. STRENGTH OF THE PI/INSTITUTIONAL SUPPORT (FOR FELLOWSHIP GRANTS): IS THE PI DEDICATED TO ASSISTING IN THE EXECUTION AND COMPLETION OF THE PROJECT? IS THE PI OF GOOD STANDING IN THE FIELD OF LUNG CANCER RESEARCH? DOES THE PI HAVE SUFFICIENT GRANT SUPPORT FOR THE FELLOW TO COMPLETE THE PROJECT IF REQUIRED? DOES THE INSTITUTION HAVE THE NECESSARY RESOURCES TO SUPPORT THE PROJECT? SCORES WILL RANGE FROM 1-5. 5 - OUTSTANDING 4 - EXCELLENT 3 - GOOD 2 - POOR 1 - UNACCEPTABLE TOTAL SCORES WILL THEN BE TABULATED, AVERAGED, AND THE CANDIDATE RANKED. THE COMMITTEE WILL MEET BY CONFERENCE CALL TO SELECT THE AWARDEES. 3. PROGRESS REPORTS FROM YEAR 1 WILL BE REVIEWED BY THE COMMITTEE CHAIR. METHOD USED TO ACCCOUNT FOR EXPENDITURES: SCHEDULE F, PART I, LINE 3: BUDGET REVIEW AND APPROVAL WAS REQUIRED FOR EACH CONFERENCE. 1 AWARDED FELLOWSHIP GRANTS TO INDIVIDUALS FOR THE STUDY OF LUNG CANCER 7 242273 SCHEDULE I, PART 1, LINE 2; V. GRANT REVIEW CRITERIA 1. GRANTS WILL BE INITIALLY REVIEWED BY THE COMMITTEE CHAIR FOR COMPLETENESS. INCOMPLETE SUBMISSIONS OR GRANTS SUBMITTED AFTER THE DEADLINE WILL BE RETURNED TO THE PI IN 48 HOURS. 2. EACH MEMBER OF THE SCIENTIFIC REVIEW COMMITTEE WILL RIGOROUSLY REVIEW THE APPLICATIONS. APPLICATIONS WILL BE SCORED ON FOUR CRITERIA: A. POTENTIAL OF THE CANDIDATE: IS THE CANDIDATE COMMITTED TO A CAREER IN LUNG CANCER RESEARCH? DOES THE CANDIDATE HAVE BASIC TRAINING RELATED TO THE PROJECT PROPOSED? PUBLISHED/SUBMITTED PAPERS OR ABSTRACTS CURRENT OR PENDING GRANT SUBMISSIONS STRONG LETTERS OF SUPPORT B. SCIENTIFIC MERIT OF THE PROJECT: IS THE PROPOSAL ORIGINAL? IS THE PROPOSAL CLEAR AND CONCISE? ARE THE SPECIFIC AIMS REASONABLE? IS THE METHODOLOGY REASONABLE TO ACCOMPLISH THE OBJECTIVES? CAN THE PROJECT BE COMPLETED IN THE TWO YEAR TIME FRAME? C. SIGNIFICANCE OF THE PROJECT: IS THE PROJECT WITHIN THE IASLC SCOPE? WHAT WILL THIS INFORMATION CONTRIBUTE TO KNOWLEDGE IN THIS FIELD? DO THESE RESULTS SIGNIFICANTLY IMPROVE THE APPLICATION OF KNOWLEDGE OF LUNG CANCER? WILL THESE DATA STIMULATE FURTHER SCIENTIFIC RESEARCH INTO LUNG CANCER? D: STRENGTH OF THE PI/INSTITUTIONAL SUPPORT (FOR FELLOWSHIP GRANTS): IS THE PI DEDICATED TO ASSISTING IN THE EXECUTION AND COMPLETION OF THE PROJECT? IS THE PI OF GOOD STANDING IN THE FIELD OF LUNG CANCER RESEARCH? DOES THE PI HAVE SUFFICIENT GRANT SUPPORT FOR THE FELLOW TO COMPLETE THE PROJECT IF REQUIRED? DOES THE INSTITUTION HAVE THE NECESSARY RESOURCES TO SUPPORT THE PROJECT? SCORES WILL RANGE FROM 1 TO 5: OUTSTANDING EXCELLENT GOOD POOR UNACCEPTABLE TOTAL SCORES WILL THEN BE TABULATED, AVERAGED, AND THE CANDIDATE RANKED. THE COMMITTEE WILL MEET BY CONFERENCE CALL TO SELECT THE AWARDEES. 3. PROGRESS REPORTS FROM YEAR ONE WILL BE REVIEWED BY THE COMMITTEE CHAIR. 1 X X X 0 0 0 0 0 0 0 0 0 PAUL A BUNN JR MD 250000 0 0 0 11000 0 0 0 32044 0 293044 0 0 0 JOHN WETHERINGTON DBA 180000 0 0 0 0 0 0 0 16785 0 196785 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 PIA HIRSCH, DIRECTOR OF EDUCATION AND FRED HIRSCH, MD, PHD, ARE SPOUSES. FORM 990, PART VI, SECTION B, LINE 11 THE TREASURER AND THE FINANCE COMMITTE REVIEW THE RETURN PRIOR TO THE FILING OF FORM 990. THE TAX RETURN IS AVAILABLE TO THE BOARD FOR REVIEW FOLLOWING THE FILING OF FORM 990. FORM 990, PART VI, SECTION B, LINE 12C THROUGH YEARLY REVIEWS FORM 990, PART VI, SECTION B, LINE 15 THROUGH YEARLY REVIEWS FORM 990, PART VI, SECTION C, LINE 19 AVAILABLE UPON REQUEST THE ORGANIZATION'S FINANCE COMMITTEE PROVIDES OVERSIGHT FOR AUDIT OF THE FINANICAL STATEMENTS AND THE SELECTION OF THE INDEPENDENT ACCOUNTANT.